Patients who received posaconazole at 5 mg/kg body weight b.i.d. had a median trough level of 134 μg/L.
Pediatric patients who received posaconazole at 4 mg/kg body weight t.i.d. had a median trough level of 383 μg/L.
In TNF-high patients, the median trough serum levels of infliximab were below the detection limit (<0.1 μg/ml) at 3 and 6 mg/kg but were greater than 2 μg/ml at 10 mg/kg, whereas the levels were approximately 1 μg/ml for each dosage group in TNF-low patients.
Median FK778 trough levels were within the targeted ranges of 150 200 μg/mL (high level FK778), 100 150 μg/mL (mid level FK778) and 50 100 μg/mL (low level FK778) by days 3, 4, and 5 in all dose groups and maintained to week 4 as protocol-specified.
Meanwhile, in patients with poor clinical response (EULAR no response, high disease activity), the median trough serum level was undetectable (<0.1 μg/ml).
Median VPA trough level over the whole treatment period was 68 μg/ml (44 97), due to necessary dose reductions.
These patients were grouped according to their median vancomycin trough level; < 10 μg/mL, 10 μg/mL to < 15 μg/mL, and ≥ 15 μg/mL.
These patients were grouped according to their median vancomycin trough level over the study period; < 10 μg/mL, 10 μg/mL to < 15 μg/mL, and ≥ 15 μg/mL.
In TNF-low patients, the median trough serum infliximab levels were equivalent to or greater than the threshold level (1 μg/ml) in all groups (3, 6 and 10 mg/kg).
However, in TNF-high patients, the median trough serum infliximab levels were undetectable at both 3 and 6 mg/kg doses, in contrast to the 10 mg/kg dose, at which a high level (>2 μg/ml) was maintained.
